Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP

Completed Phase 1 NCT04033068

Study Description

This study is designed to investigate, at first, safety and tolerability of a novel liquid vaccine formulation named MV-ZIKA-RSP, in healthy adults aged 18 to 55 years

Study Details

Registry ID:
NCT04033068
Conditions:
Zika Virus Infection
Phase:
Phase 1
Target Enrollment:
48 participants
Start Date:
Age Range:
18–55 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →